The use of mifepristone in the treatment of neuropsychiatric disorders.
about
Antiglucocorticoid treatments for mood disordersAntiglucocorticoid treatments for mood disordersPostnatal glucocorticoid-induced hypomyelination, gliosis, and neurologic deficits are dose-dependent, preparation-specific, and reversibleClinical applications of mifepristoneDual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugsHypothalamic-pituitary-adrenocortical axis dysfunction in epilepsy.Cortisol's effects on hippocampal activation in depressed patients are related to alterations in memory formationThree-factor models versus time series models: quantifying time-dependencies of interactions between stimuli in cell biology and psychobiology for short longitudinal data.Effect of the glucocorticoid receptor antagonist RU486 on MK-801 induced behavioural sensitisation.The selective glucocorticoid receptor antagonist CORT 108297 decreases neuroendocrine stress responses and immobility in the forced swim test.Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume.Hormone treatment of depression.Longitudinal changes in cortisol secretion and conversion to psychosis in at-risk youth.Chronic stress effects on hippocampal structure and synaptic function: relevance for depression and normalization by anti-glucocorticoid treatment.The neurobiological correlates of childhood adversity and implications for treatment.Mifepristone in the central nucleus of the amygdala reduces yohimbine stress-induced reinstatement of ethanol-seekingPersistent disruption of a traumatic memory by postretrieval inactivation of glucocorticoid receptors in the amygdalaHypothalamic Proteomic Analysis Reveals Dysregulation of Glutamate Balance and Energy Metabolism in a Mouse Model of Chronic Mild Stress-Induced Depression.Divergent regulation of distinct glucocorticoid systems in alcohol dependence.Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatmentThe role of the glucocorticoids in developing resilience to stress and addiction.Preclinical assessment for selectively disrupting a traumatic memory via postretrieval inhibition of glucocorticoid receptors.Early life stress as an influence on limbic epilepsy: an hypothesis whose time has come?Stress and IL-1beta contribute to the development of depressive-like behavior following peripheral nerve injury.Mifepristone decreases depression-like behavior and modulates neuroendocrine and central hypothalamic-pituitary-adrenocortical axis responsiveness to stress.Inflammatory mediators of cognitive impairment in bipolar disorder.Corticosteroid receptor signalling modes and stress adaptation in the brain.The modulatory role of the lateral septum on neuroendocrine and behavioral stress responses.Non-steroidal glucocorticoid receptor antagonists: the race to replace RU-486 for anti-glucocorticoid therapy.Regulated expression of the interferon-beta gene in mice.Hypothalamic-pituitary-adrenocortical system dysregulation and new treatment strategies in depression.Targeting glucocorticoid receptors prevents the effects of early life stress on amyloid pathology and cognitive performance in APP/PS1 mice.The influence of stress hormones and aggression on cooperative behaviour in subordinate meerkats.
P2860
Q24187372-F70BD577-36FF-42EB-B5A4-1BBAB11FFD8FQ24242845-1E662754-1E03-471E-9741-256F2F06561AQ27311426-DBFC9A57-141A-4520-BEE2-607AF06510C5Q28278425-5070ABC2-75C0-418A-89AA-067BB04A89C9Q28305100-C57D45D4-D113-4C26-A409-EC3E3B203441Q30250270-9EF48889-9BBA-495D-8812-89CC1F67511FQ30498379-546F0CC0-DA89-44E5-8B75-00218A610F5BQ31077402-C03F6BF4-43AF-4339-83C7-A735B8DF8F81Q33590375-BF40D9A7-0CCA-44D2-97D2-3FE88EAF6652Q33817003-3B2F7913-B947-484F-9FD6-D69DD2B1C280Q33849008-C94AA516-6ADE-4F8A-ACE5-AC1AE26BF350Q34177698-4B376054-D893-436E-A3BB-4C1914CD3638Q34639853-472512AF-5089-415E-9632-564CFAC7D843Q34689894-806D4685-2242-4C6D-955A-A1489CAB8F9CQ35743326-C62C81EA-FE34-4649-A175-1F6487680EC3Q35760239-60D94678-8549-40A1-BE72-DA8678983966Q35995115-E8CBC02B-374F-4554-BEA7-CCEEC01C55C0Q36031835-F9F1FACC-9C46-479A-BB45-9C017829BBFAQ36233582-32A3B9E6-3AB6-40C0-8E21-406DE4150200Q36442033-2E5CB49A-09A5-4730-8CAA-F1EEA3C295CBQ37061076-BA4763BD-4EF7-48AE-AD8C-513CF477BCC3Q37156512-FAB3E2D8-E032-4632-BF6B-29AFA40D5C57Q37388479-2D2886EB-1F5F-41D3-9647-D354D7970149Q37558014-52D9413C-C179-4F75-939F-147B624659C7Q37602526-2081F2D1-386D-4941-93CF-B410333F28EAQ38215023-58546FAC-F626-4CF0-8575-A82C4F06A714Q38471565-27A692C9-115A-4997-B998-94FF5D61D144Q42682630-6937CF26-D30B-4A6F-BFA3-248D217B8322Q43167314-B57DA0A4-BC7D-4803-9DE8-DD272F8B3104Q45869589-FEF96B57-53C2-4BDD-8DCB-CCE928B682A7Q45934195-0B4CDB90-3E82-455F-AAE1-C9005249AF6FQ53081269-18D38247-3541-468B-B1E9-CF260E4D813AQ53719201-DC22B3F0-D173-47A6-95CE-EB0407B0534F
P2860
The use of mifepristone in the treatment of neuropsychiatric disorders.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The use of mifepristone in the treatment of neuropsychiatric disorders.
@ast
The use of mifepristone in the treatment of neuropsychiatric disorders.
@en
type
label
The use of mifepristone in the treatment of neuropsychiatric disorders.
@ast
The use of mifepristone in the treatment of neuropsychiatric disorders.
@en
prefLabel
The use of mifepristone in the treatment of neuropsychiatric disorders.
@ast
The use of mifepristone in the treatment of neuropsychiatric disorders.
@en
P1476
The use of mifepristone in the treatment of neuropsychiatric disorders.
@en
P2093
Charles DeBattista
Joseph Belanoff
P304
P356
10.1016/J.TEM.2006.02.006
P577
2006-03-10T00:00:00Z